1. Evaluation of anti-proliferative and anti-inflammatory activities of Pelagia noctiluca venom in Lipopolysaccharide/Interferon-γ stimulated RAW264.7 macrophages.
- Author
-
Ayed Y, Sghaier RM, Laouini D, and Bacha H
- Subjects
- Animals, Anti-Inflammatory Agents isolation & purification, Cell Line, Cell Proliferation physiology, Cell Survival drug effects, Cell Survival physiology, Cnidarian Venoms isolation & purification, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical methods, Humans, K562 Cells, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear metabolism, Macrophages metabolism, Mice, Nitric Oxide Synthase Type II antagonists & inhibitors, Nitric Oxide Synthase Type II metabolism, Anti-Inflammatory Agents pharmacology, Cell Proliferation drug effects, Cnidarian Venoms pharmacology, Interferon-gamma toxicity, Lipopolysaccharides toxicity, Macrophages drug effects
- Abstract
Components of Pelagia noctiluca (P. noctiluca) venom were evaluated for their anticancer and nitric Oxide (NO) inhibition activities. Three fractions, out of four, obtained by gel filtration on Sephadex G75 of P. noctiluca venom revealed an important selective anti-proliferative activity on several cell lines such as human bladder carcinoma (RT112), human glioblastoma (U87), and human myelogenous leukemia (K562) but not on mitogen-stimulated peripheral blood mononuclear cells. Interestingly, P. noctiluca components showed an important dose-dependent anti-inflammatory activity, through inhibition of NO production via transcriptional regulation of Inducible NO Synthase (iNOS), in IFN-γ/LPS stimulated RAW 264.7 macrophages. These data strongly suggest that P. noctiluca venom could be used as a natural inhibitor of cancer cell lines and a potent anti-inflammatory agent for the treatment of anti-inflammatory diseases., (Copyright © 2016 Elsevier Masson SAS. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF